G&E Herbal Biotechnology Co., Ltd.

As of June 30, 2026, G&E Herbal Biotechnology Co., Ltd. carries a market capitalization of 2.04B, placing it among publicly traded companies globally. Its enterprise value stands at 1.62B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, G&E Herbal Biotechnology Co., Ltd. has 68.82M shares outstanding.

As of June 30, 2026, G&E Herbal Biotechnology Co., Ltd. trades at a trailing price-to-earnings ratio of 24.40. The price-to-sales ratio is 9.76, and the price-to-book ratio stands at 2.32.

As of June 30, 2026, G&E Herbal Biotechnology Co., Ltd. trades at an EV/EBITDA multiple of 17.26 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.49 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 19.48 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. G&E Herbal Biotechnology Co., Ltd. trades at an EV/FCF ratio of 89.10, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.62B versus a market cap of 2.04B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, G&E Herbal Biotechnology Co., Ltd. maintains a current ratio of 4.69, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.62, indicating moderate leverage, while an interest coverage ratio of 4,679.70 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, G&E Herbal Biotechnology Co., Ltd. posted a return on equity (ROE) of 9.91, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 9.06 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.67, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 9.82, useful for judging operating efficiency across full business cycles. The company generates approximately 5.64M in revenue per employee across its workforce of 38.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.64 indicates how many times G&E Herbal Biotechnology Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, G&E Herbal Biotechnology Co., Ltd. recorded 3.01M in income tax expense. That works out to an effective tax rate of 3.37, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 89.26M, leaving 86.25M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, G&E Herbal Biotechnology Co., Ltd.'s stock has declined approximately 40.61% over the past 52 weeks. The 50-day moving average sits at 28.51, while the 200-day moving average is 32.04.

Over the twelve months ended June 30, 2026, G&E Herbal Biotechnology Co., Ltd. generated 215.61M in revenue and converted that into 86.25M in net income, yielding earnings per share of 1.21. EBITDA reached 93.59M, while operating income came in at 82.92M.

As of June 30, 2026, G&E Herbal Biotechnology Co., Ltd. holds 425.82M in cash and equivalents against 5.47M in total debt, resulting in a net debt position of -138.88M. Total book value stands at 876.54M, with working capital of 371.55M providing operational flexibility.

G&E Herbal Biotechnology Co., Ltd. produced 21.07M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.95M in capital expenditures, free cash flow totaled 18.11M - equivalent to 0.25 per share.

Over the twelve months ended June 30, 2026, G&E Herbal Biotechnology Co., Ltd. posted a gross margin of 80.49, reflecting its pricing power and cost economics. The operating margin of 38.46 and net profit margin of 40.00 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, G&E Herbal Biotechnology Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 0.86, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.24, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to G&E Herbal Biotechnology Co., Ltd. shareholders.

G&E Herbal Biotechnology Co., Ltd.'s most recent stock split took place on July 28, 2026 with a 25:27 split ratio.

As of June 30, 2026, G&E Herbal Biotechnology Co., Ltd. has an Altman Z-Score of 13.26, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.